Company intelligence / Profile preview

Tenza

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Tenza is developing a platform that uses engineered probiotic microbes as living drug factories. These microbes are designed to synthesize and deliver protein therapeutics directly at the site of disease within the body, aiming for more potent, painless, and cost-effective treatments compared to conventional injected biologics. The company is currently in the research and development stage with no clinical results yet published

Therapeutic areas: Other
Modalities: Live biotherapeutic product therapyProteinSynthetic biology-based therapyMicrobial therapy
Industry: Biotech

Partnerships

No major partnerships publicly disclosed.

Beyond the preview

Go deeper on Tenza.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tenza.

Explore the full profile